ARK Genomic Revolution ETF vs Prologis Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.45, while Prologis Inc trades at $142.13 (market cap $131.34B). The key difference: Prologis Inc pays a 3.04% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | PLD | |
|---|---|---|
Sector | Sector/Thematic | Real Estate |
52-Week High | $43.57 | $148.74 |
52-Week Low | $23.09 | $104.08 |
Market Cap | — | $131.34B |
Enterprise Value | — | $165.21B |
Dividend Yield | — | 3.04% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →